Company intelligence / Profile preview

Goldman Sachs

New York City, New York, United Statesgoldman.com ↗

Ownership: Private
Employees: ~45000
Development stage: Commercial

Overview

Goldman Sachs has launched its first dedicated life sciences venture fund—West Street Life Sciences I—with $650 million raised to invest primarily in early and mid-stage therapeutic and diagnostics/tool companies. The fund focuses on precision medicine, genetic medicine, cell therapy, immunotherapy, synthetic biology and artificial intelligence within the healthcare sector. About $90 million has already been invested across five portfolio biotechs including Moma Therapeutics and Nested Therapeutics

Modalities: Small moleculeMonoclonal antibodyCell therapyGene therapyImmunotherapySynthetic biology
Industry: Investors

Beyond the preview

Go deeper on Goldman Sachs.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Goldman Sachs.

Explore the full profile